Outcomes of Surgical Treatment Using a Custom-made Device for Total Ankle and Talar Replacement in the Management of Severe Cases of Bone Loss or Bone Compromise: a Pilot Study.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- To evaluate the survival of the FAR implant in a cohort of patients treated at the Orthopaedic and Traumatology Clinic I of the Rizzoli Orthopaedic Institute, with follow-up at 1, 3, 6, 12, 24, and 36 months.
研究概览
简要总结
On February 17th, 2021, the FDA officially approved the use of the first patient-specific 3D-printed talar implant for compassionate use. This is a patient-specific talar spacer designed to completely replace the talus for the treatment of talar avascular necrosis. The implant represents an alternative to other surgical procedures that allows joint preservation.
Recently, at the First Clinic of the Rizzoli Orthopaedic Institute, a prosthetic device has been developed that combines the tibial and meniscal components of a FAR-type ankle prosthesis (Adler Ortho) with a total talus replacement implant. Since the device is patient-specific and implanted using custom-made cutting guides, it reduces surgical invasiveness on surrounding bone structures as well as on ligamentous and tendinous structures, thereby preserving ankle function as much as possible.
The customization is based on a next-generation prosthetic model produced using additive manufacturing technology and featuring hypoallergenic properties, as it is made of a titanium alloy and treated with a nitriding process.
The aim of this study is therefore to evaluate the outcomes of this prosthetic device over time.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 35 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •**INCLUSION CRITERIA:**
- •Male or female patients aged between 35 and 75 years.
- •Pathology of the tibiotalar joint requiring surgical intervention with prosthetic replacement.
- •Severe cases of bone loss or talar bone compromise.
- •Customisation performed at the Rizzoli Orthopaedic Institute.
- •Signed informed consent for participation in the study.
- •Patients must be prepared and motivated to comply with preoperative and postoperative investigations, rehabilitation protocols, follow-up schedules, and study questionnaires.
排除标准
- •Patients unable to understand or provide informed consent.
- •Pregnant women.
- •Body mass index (BMI) >
- •Refusal to sign the informed consent form for study participation.
- •Substance abuse or psychological disorders that may interfere with adherence to rehabilitation and postoperative assessment protocols.
- •Known hypersensitivity to device materials.
- •Active or suspected latent infection in or around the affected ankle joint.
- •Previous orthopaedic surgery on the lower limbs within the last year, or planned orthopaedic surgery within one year (excluding ankle replacement).
- •Presence of neuromuscular or neurosensory deficits limiting the ability to assess device safety and efficacy.
- •Diagnosis of systemic disease (e.g., systemic lupus erythematosus) or metabolic disorder (e.g., Paget's disease of bone) leading to progressive bone deterioration.
- •Immunosuppression or excessive steroid therapy beyond physiological requirements (e.g., >30 days).
- •Pregnant and/or fertile women.
结局指标
主要结局
To evaluate the survival of the FAR implant in a cohort of patients treated at the Orthopaedic and Traumatology Clinic I of the Rizzoli Orthopaedic Institute, with follow-up at 1, 3, 6, 12, 24, and 36 months.
时间窗: february 2022 - march 2028
次要结局
- Objective and subjective clinical and radiographic evaluation of the implant To assess ankle joint function using radiographic (X-ray) imaging(36 months)
- To evaluate clinical parameters using: The American Orthopaedic Foot and Ankle Society (AOFAS) score The Manch(36 months)
研究者
Cesare Faldini
Principal Investigator
Istituto Ortopedico Rizzoli